Previous 10 | Next 10 |
home / stock / pclo:cc / pclo:cc news
PharmaCielo is actively working with more than 24 customers in 15 countries globally, with a focus on psychoactive APIs and dried flower. The Company recently made its first shipment of THC Distillate and THC-Dominant Dried Flower to a customer in Australia that will be supplying these products ...
The Company has products in various stages of testing and sales with more than 40 customers in 11 countries, with continued growth expected for the year. Q1 2023 revenue of $786,498; Adjusted EBITDA loss of $1.9 million. PharmaCielo continues to focus on operating efficiently, with overhead exp...
Represents PharmaCielo's first shipment to South Africa, which has well-established export networks in the UK and Australia, and other potential markets, globally. Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - May 16, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCi...
During 2022, PharmaCielo made shipments to 23 clients in 9 countries, with continued growth expected for 2023. The Company's measured investments in revenue-generating sales channels resulted in revenues of $5.3 million in 2022, almost three-times more than the $1.9 million reported in 2021. Co...
Will bring unique high-THC Colombian strains owned by PharmaCielo to Europe for the first time. Combines PharmaCielo's expertise in producing premium medicinal cannabis products, with CANNPRISMA's conversion capabilities, to bring patients in Europe the highest quality high-THC flower product ...
TSX Venture Exchange Stock Maintenance Bulletins Canada NewsWire VANCOUVER, BC , April 14, 2023 /CNW/ - TSX VENTURE COMPANIES BULLETIN TYPE: Cease Trade Order BULLETIN DATE: April 14, 2023 TSX Venture Company A Cease ...
PharmaCielo Receives Purchase Order for API from Brazilian Pharmaceutical Company - Represents Third Customer in the Country Canada NewsWire PharmaCielo has received a purchase order for CBD Isolate as an API, which will be used by a large pharmaceutical company in Brazil ...
PharmaCielo Announces Continued Progress on Efficiency Initiatives to Accelerate Profitability and Intention to Amend Warrant Terms Canada NewsWire Steady progress against the efficiency plans initiated in mid-2021 with the transition to the current senior management team. Exp...
PharmaCielo Receives First Commercial Purchase Order from Ease Labs Pharma - Proprietary API a Key Ingredient in Recently Approved Product for Brazilian Market Canada NewsWire Ease Labs Pharma, a global pharmaceutical company headquartered in Brazil , has received regulato...
PharmaCielo Announces First Shipment of Pharmaceutical Grade Cannabis Extract to Customer in Morocco Canada NewsWire Represents PharmaCielo's first shipment to Africa . Morocco is pioneering the commercialization of cannabinoid products on the African continent and w...
News, Short Squeeze, Breakout and More Instantly...
Pharmacielo Ltd. Company Name:
PCLO:CC Stock Symbol:
TSXVC Market:
The proposed acquisition of Siam Ventures, which provides contract manufacturing services through a subsidiary, will act as a gateway to large Asian markets for PharmaCielo product. Experienced investor, businessman and lawyer Louis Desmarais, the current Chairman and CEO of Siam Ventures, w...
2024-03-27 17:08:02 ET CEO of PharmaCielo, David Attard speaks to shareholders about the short seller report In early March, Hindenburg Research issued a short seller report targeting PharmaCielo's credibility and its stock. Moreover, the Company believes that this report represen...
2024-03-27 17:08:02 ET A Canadian company with Colombian operations PharmaCielo is a global company, headquartered in Canada. They are focusing on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related produ...